# Racetams

> The racetams are a family of synthetic compounds sharing a 2-pyrrolidone core, of which piracetam — synthesised at UCB in Belgium in 1964 by Corneliu Giurgea — was the first. Giurgea coined the word…

Canonical: https://wiki.soapbox.community/wiki/Racetams
Section: Substances and pharmacology
Last updated: 2026-10-20
Publisher: Library of Ashurbanipal (Van Kush Family Research Institute), https://wiki.soapbox.community

The **racetams** are a family of synthetic compounds sharing a 2-pyrrolidone core, of which **piracetam** — synthesised at UCB in Belgium in 1964 by Corneliu Giurgea — was the first. Giurgea coined the word **nootropic** for it in 1972, from Greek *nous* (mind) and *trepein* (to bend), and set out criteria that included enhancement of learning, protection against disruption, and **very low toxicity** — the last being the part most often dropped when the term is used commercially.

## The family

- **Piracetam** — the parent. The most studied and the mildest.
- **Aniracetam** — fat-soluble, short half-life, AMPA-modulating.
- **Oxiracetam** — reported as more stimulating.
- **Pramiracetam** — high-affinity choline uptake.
- **Phenylpiracetam** — a phenyl-substituted piracetam, developed in the Soviet space programme as **Phenotropil**; markedly stimulating, and **banned by WADA** as a stimulant.
- **Levetiracetam** — pharmacologically a member of the family, and a mainstream **anticonvulsant** (Keppra), which is a useful reminder that this scaffold is not inert.

## Mechanism, honestly stated

**The mechanism is not settled.** Proposals include modulation of AMPA-type glutamate receptors, effects on membrane fluidity, improved mitochondrial function, and increased high-affinity choline uptake. Piracetam is **not** a direct cholinergic agonist. The standard practice of pairing it with a choline source is an inference from the choline-uptake finding and from user reports of headache, not from an established requirement.

## Evidence

This is where the popular account and the literature part company. The evidence for piracetam is **strongest in clinical populations** — cognitive decline in the elderly, post-stroke aphasia, cortical myoclonus, some breath-holding and dyslexia indications — and **weak to absent in healthy young adults**, who are essentially the entire consumer market. It was never approved by the FDA for any indication and is not lawfully sold as a dietary supplement in the United States, though it is a prescription or over-the-counter medicine in much of Europe.

The Amplification Framework places the racetams in the **modulator** role of the cholinergic stack — the position L-methylfolate is proposed to occupy for monoamines.

## The Soviet lineage

A substantial body of racetam and adjacent nootropic research was carried out in the Soviet Union and published in Russian; phenylpiracetam is the best-known product of it. The Institute's corpus treats this as an **orphaned tradition** — real work that never entered the English-language literature, and which is neither validated nor refuted so much as unread.

## Cautions

- **Headache** is the commonest reported effect, and the reason choline is usually paired.
- Piracetam has **antiplatelet** activity and is used clinically for that; it matters alongside anticoagulants and before surgery.
- **Renal clearance** — dose reduction is indicated in renal impairment.
- **Phenylpiracetam** is a stimulant with tolerance and a competition ban, not a stronger piracetam.
- **Legal status varies by country** and the US position is not the global one.
- The T-0 self-observation method in the Institute's 2016 material is a **notebook convention** for logging effects against a timeline, not a dosing protocol.

See also: Choline Donors · The Amplification Framework · L-Methylfolate · Stack Substances